Mitochondria Transfer to CD4⁺ T Cells May Alleviate Rheumatoid Arthritis by Suppressing Pro-Inflammatory Cytokine...

Area of Science:

• Immunometabolism
• T cell biology
• Autoimmune disease pathogenesis

Background:

• CD4+ T cells drive rheumatoid arthritis (RA) pathogenesis by producing inflammatory cytokines like TNF-α.
• Current RA therapies targeting T cells and TNF-α have limitations, including patient refractoriness and side effects.
• CD4+ T cell function is influenced by metabolic pathways, suggesting immunometabolism as a therapeutic target.

Purpose of the Study:

• To investigate the role of mitochondrial dysfunction in CD4+ T cells from RA patients.
• To explore the therapeutic potential of restoring mitochondrial function in T cells for RA treatment.

Main Methods:

• Analysis of mitochondrial function and citric acid cycle metabolites in CD4+ T cells from RA patients.
• In vitro treatment of RA-associated T cells with purified exogenous mitochondria.
• Assessment of cytokine production (TNF-α, IL-17A) and disease severity in a humanized mouse model.

Main Results:

• CD4+ T cells from RA patients exhibit impaired mitochondrial function and reduced levels of key metabolites.
• Mitochondria transfer restored metabolic defects, reduced pro-inflammatory cytokine production (TNF-α, IL-17A), and ameliorated RA-like disease in mice.
• Ex vivo metabolic re-engineering of T cells via mitochondria transfer demonstrates anti-inflammatory properties.

Conclusions:

• Mitochondrial dysfunction in CD4+ T cells is implicated in RA pathogenesis.
• Exogenous mitochondria transfer represents a novel cell engineering strategy to confer anti-inflammatory properties.
• This immunometabolic approach holds promise for treating RA and other rheumatologic diseases.